The Effect of Hyperhomocysteinemia on Motor Symptoms, Cognitive Status, and Vascular Risk in Patients with Parkinson’s Disease

Table 1

Demographic and clinical characteristics and values of vitamin B12 and folic acid in PD patients.

	PD ()
Age (years)	68.4 ± 8.95
Duration of disease (years)	7.0 ± 5.75
Age of PD onset (years)	61.4 ± 10.92
mHY stage	2.2 ± 0.99
UPDRS-II score	12.1 ± 6.86
UPDRS-III score	17.4 ± 8.37
UPDRS tremor subscore	2.3 ± 1.56
UPDRS rigidity subscore	1.4 ± 0.90
UPDRS bradykinesia subscore	7.1 ± 3.29
UPDRS gait/postural instability subscore	3.4 ± 2.99
MMSE score	24.2 ± 4.21
Vitamin B12 (pg/ml)	344.4 ± 206.54
Folic acid (ng/ml)	9.3 ± 3.74

Data reported as the mean ± SD.
PD: Parkinson’s disease; mHY: modified Hoehn and Yahr Staging Scale; UPDRS: Unified Parkinson’s Disease Rating Scale; MMSE: Mini-Mental State Examination.